#Enterobacterales
LightNews LightNews
tryangregory.bsky.social
Not now, carbapenemase-producing Enterobacterales.

www.cidrap.umn.edu/antimicrobia...
July 15, 2025 at 8:38 PM
drneilstone.bsky.social
New paper from my colleagues at UCLH

Nearly 70% (!!!) resistance to Cefiderocol in NDM positive bacteria.

Cefiderocol...we hardly knew ye...

Perfect timing for World Antimicrobial Awareness Week #waaw24 #IDSky

academic.oup.com/jac/advance-...
Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
AbstractBackground. Carbapenemase-producing Enterobacterales (CPE) pose difficult therapeutic challenges. We aimed to characterize antimicrobial resistance
academic.oup.com
November 18, 2024 at 10:34 AM
sciam.bsky.social
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 percent in recent years. Scientists say people receiving treatment in hospitals are at highest risk
CDC Sounds Alarm over ‘Nightmare Bacteria’ That Resist Last-Resort Antibiotics
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 percent in recent years. Scientists say people receiving treatment in hospitals are at highe...
www.scientificamerican.com
September 25, 2025 at 12:58 PM
ilyasalav.bsky.social
My main postdoc paper is now out in @natureportfolio.nature.com npj Antimicrobials and Resistance! www.nature.com/articles/s44.... Using flow cytometry, we show that the nucleoside analogues azidothymidine, didanosine, stavudine, and trifluridine reduced transfer of AMR plasmids pCT and pKpQIL (1/3)
Mechanistic insights into plasmid transfer inhibition in Enterobacterales by nucleoside analogues - npj Antimicrobials and Resistance
npj Antimicrobials and Resistance - Mechanistic insights into plasmid transfer inhibition in Enterobacterales by nucleoside analogues
www.nature.com
April 14, 2026 at 5:29 PM
ecdc.europa.eu
#JustPublished:
Rapid risk assessment - Carbapenem-resistant Enterobacterales – third update.

Increase in carbapenem-resistant Enterobacterales (CRE) poses a significant threat to patients and healthcare systems in the EU/EEA.

Press release: bit.ly/4hnx9RK
Full report: bit.ly/3Q5cy8R

#AMR
Increase in carbapenem-resistant Enterobacterales (CRE) poses a significant threat to patients and healthcare systems in the EU/EEA
Increasing incidence of bloodstream infections with Enterobacterales resistant to carbapenem antibiotics poses a significant threat to patients and healthcare systems in the EU/EEA.
bit.ly
February 3, 2025 at 4:56 PM
usatoday.com
A recent study from the CDC found a nearly 70% increase in the spread of carbapenem-resistant Enterobacterales (CRE).
Drug-resistant 'nightmare' bacterial infections are on the rise, CDC warns. What to know.
A recent study from the CDC found a nearly 70% increase in the spread of carbapenem-resistant Enterobacterales (CRE).
bit.ly
October 11, 2025 at 12:30 PM
altcdc.altgov.info
Whew, enough about vaccine-preventable diseases for now 💉

This week's #MMWR is all about pathogens that (mostly) *aren't* vaccine-preventable at the moment:
🫁 Mycoplasma pneumoniae
🥵 Parvovirus B19
🧼 Enterobacterales

Time for the highlight of everyone's week, our #AltComms briefing!
June 27, 2025 at 12:14 AM
drtimothyli.bsky.social
Proposed algorithm for the management of MBL-producing Enterobacterales

doi.org/10.1016/j.cm...
November 10, 2024 at 3:43 PM
texugo-huffpuff.bsky.social
areadoanalistaclinico.blogspot.com/2026/05/bact...
Bacteriologia Clínica - Enterobacterales e Bacilos Gram-Negativos Não Fermentadores: Abordagem Bioquímica e Identificação
Bacteriologia Clínica Enterobacterales e Bacilos Gram-Negativos Não Fermentadores:  Abordagem Bioquímica e Identificação A ordem Enterobact...
areadoanalistaclinico.blogspot.com
May 25, 2026 at 10:25 AM
jidjournal.bsky.social
Meropenem–Colistin Combination Mitigates Porin-Associated Carbapenem Resistance Development in Ertapenem-Mono-Resistant Enterobacterales

🔁 Repost
🔗 https://t.co/1eQbLlRwnp
October 2, 2026 at 9:21 PM
cidrap.bsky.social
Study finds ‘alarming’ global prevalence of multidrug-resistant bacterial colonization

A review and meta-analysis of 89 studies shows the global prevalence of carbapenem-resistant Enterobacterales colonization is 14%.

www.cidrap.umn.edu/a...
December 8, 2025 at 9:27 PM
absteward.bsky.social
Wow!
🆕🔥🔴Multicenter OL NI RCT
Oral fosfomycin (3 g once daily) was noninferior to continued intravenous therapy with carbapenems or BLBLIs when used as oral transition therapy for complicated UTIs caused by ESBL-producing Enterobacterales #IDSky #utisky
academic.oup.com/cid/article-...
Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter,...
Switching from intravenous antibiotics to oral fosfomycin was noninferior to continuing intravenous therapy for complicated urinary tract infections caused
academic.oup.com
June 18, 2026 at 4:09 PM
pulmcrit.bsky.social
🚩reminder to be wary of ceftriaxone-resistant enterobacterales species (eg E coli)

even if the lab results show “sensitivity” to piptazo, piptazo therapy may fail.

#emimcc
sebpoule.bsky.social Sébastien Poulin @sebpoule.bsky.social · Nov 23
Establishing Pip-Tazo susceptibility in CTX non-susceptible Enterobacterales: DD, Etest, VITEK 2 vs broth microdilution (🔒) #IDsky #Microsky

➡️VITEK 2 (+/- Etest)= risk of major errors

➡️VITEK 2= risk of VERY major errors (if MIC>4) 26%❗

➡️VITEK 2+DD (if MIC 8-16) could ⬇️ major & very major errors
November 23, 2024 at 5:25 PM
enuffsaysv.bsky.social
Infections of Drug-Resistant ‘Nightmare Bacteria’ Are Surging in Hospitals
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 % in recent years.
Scientific American: apple.news/ArSj1iNpZRS-...
👉all we have for help is a brain worm idiot👈
Infections of Drug-Resistant ‘Nightmare Bacteria’ Are Surging in Hospitals — Scientific American
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 percent in recent years. Scientists say people receiving treatment in hospitals are at highe...
apple.news
September 25, 2025 at 4:44 AM
josephmarcusid.medsky.social
54,576 Enterobacterales:
0.9% CREs

❌3.7% of CREs were aztreonam-S
✅98.4% of CREs were aztreonam+avibactam-S

“highly active against CREs carrying class A, B, and/or D carbapenemases with susceptibility rates of 99.4%, 98.0%, and 100%, respectively.”

#IDSky

academic.oup.com/ofid/advance...
Aztreonam-avibactam demonstrates potent activity against carbapenem-resistant Enterobacterales collected from US medical centers over a six-year period (2017–2022)
The activity of aztreonam-avibactam was evaluated against a contemporary collection of carbapenem-resistant Enterobacterales (CREs) from the US. Of the 511
academic.oup.com
April 27, 2025 at 10:06 PM
cidrap.bsky.social
Canadian hospitals seeing exponential increase in superbug incidence

Researchers say the increase in carbapenemase-producing Enterobacterales infection and colonization is being driven by in-hospital transmission.

www.cidrap.umn.edu/a...
July 15, 2025 at 8:36 PM
happysnarkygal.bsky.social
Oh goody! Just in time for RFK Jr.
PS - we’re fucked. www.scientificamerican.com/article/nigh...
CDC Sounds Alarm over ‘Nightmare Bacteria’ That Resist Last-Resort Antibiotics
The infection rate of one type of carbapenem-resistant Enterobacterales bacteria has risen by more than 460 percent in recent years. Scientists say people receiving treatment in hospitals are at highe...
www.scientificamerican.com
September 29, 2025 at 7:47 AM
boghuma.bsky.social
"The CDC said surveillance data from labs across the country showed that the incidence of carbapenem-resistant Enterobacterales infections carrying NDM genes rose 461% from 2019 through 2023. And CDC officials are worried about the implications."
www.cidrap.umn.edu/antimicrobia...
The resistance gene that’s causing ‘nightmares’ in US hospitals
www.cidrap.umn.edu
July 21, 2026 at 5:21 PM
wtmatlock.bsky.social
The formatted version of our multi-niche, multi-year plasmid genomic epidemiology study is finally available (elifesciences.org/articles/85302), but more importantly, I’d love to see future studies make use of the 1000s of Enterobacterales hybrid assemblies we generated: zenodo.org/records/7948...
Enterobacterales plasmid sharing amongst human bloodstream infections, livestock, wastewater, and wa...
A geographically and temporally restricted genomic surveillance study concludes that Enterobacterales plasmid dissemination between human and non-human niches might be occurring at greater rates than ...
elifesciences.org
December 7, 2023 at 10:38 PM
absteward.bsky.social
🔥🔥Just published 🔥🔥
IDSA AMR Guidance 2026
IDSA 2026 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections
🔺ESBL , AmpC Enterobacterales
🔺CRE
🔺DTR P. aeruginosa
🔺CRAB
🔺Stenotrophomonas maltophilia #idsky
www.idsociety.org/practice-gui...
July 27, 2026 at 4:06 PM
ofidjournal.bsky.social
The Prevalence of Multidrug Resistant Enterobacterales is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation

✅ Just Accepted
#IDSky
The Prevalence of Multidrug Resistance in Enterobacterales is Higher in Patients Undergoing Hematopoietic Stem Cell Transplantation
Antimicrobial resistance is a global public health emergency. Patients undergoing hematopoietic stem cell transplantation (HCT) are at increased risk for severe infections with multidrug-resistant organisms, although more data are needed on the relative burden of multidrug-resistant Enterobacterales (MDR-E) in immunocompromised populations.
buff.ly
January 6, 2025 at 10:11 PM
absteward.bsky.social
Happy New Year, @absteward.bsky.social style! 🎉
Kicking off 2025 with this gem:
🆕💫 How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins? #idsky #EMIMCC
journals.asm.org/doi/10.1128/...
How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins? | Antimicrobial Agents and Chemotherapy
There is a growing body of evidence supporting early transition to oral antibiotic therapy to complete treatment courses for gram-negative bloodstream infections (GN-BSI) (1–3). Most available data fo...
journals.asm.org
December 31, 2024 at 7:34 PM
germhuntermd.bsky.social
#IDSky #MedSky required reading:

Multidrug-resistant Gram-negative bacterial infections

Nenad Macesic, Anne-Catrin Uhlemann, Anton Peleg

Review in @thelancet.bsky.social

doi.org/10.1016/S014...
Figure 1 Mechanisms of action of key antibiotics for the treatment of multidrug-resistant Gram-negative bacterial infections Several classes of antibiotics are available for the treatment of multidrug-resistant Gram-negative bacterial infections. Their mechanisms of action focus on key aspects of bacterial cell function, such as inhibiting cell wall synthesis (ie, β-lactams and fosfomycin) and function (ie, polymyxins), protein synthesis (ie, aminoglycosides and tetracyclines), folic acid synthesis (ie, trimethoprim and sulphonamides), and DNA replication (ie, fluoroquinolones). Because of increasing antimicrobial resistance, novel antibiotics have been developed to overcome some of these mechanisms; for example, by inhibiting antibiotic modification (ie, β-lactamase inhibitors) or by altering entry pathways (ie, cefiderocol, which enters via iron transporters). DHF=dihydrofolic acid. PABA=para-aminobenzoic acid. THF=tetrahydrofolate. Figure 2 Diagnostic testing of multidrug-resistant Gram-negative bacteria Diagnosis of multidrug-resistant Gram-negative bacterial infections involves both species identification and antibiotic susceptibility testing. Although clinical microbiology laboratories have undergone automation of these processes and have seen the introduction of proteomic methods, such as MALDI-TOF, delays in turnaround time remain and might affect patient outcomes. New biochemical, molecular (eg, PCR), automated microscopy, and hybridisation-based rapid diagnostics now allow faster detection of antimicrobial resistance, including by testing clinical samples directly. Emerging technologies are seeking to improve both the speed of testing and provide more detailed information regarding the underlying mechanisms of antimicrobial resistance. MALDI-TOF=matrix-assisted laser desorption/ionisation time-of-flight. Figure 3 Summary of new antibiotic agents for the treatment of multidrug-resistant Gram-negative bacterial infections Green=antibiotic is reliably active in vitro and guideline recommended. Yellow=variable activity; antibiotic might be effective if in vitro susceptibility is shown, clinical data might be lacking to support routine use. Red=not recommended, likely absence of in vitro susceptibility. IV=intravenously. *Administered simultaneously via Y-site administration. †Administration was studied in combination with imipenem–cilastatin. Figure 4 Summary of IDSA and ESCMID guidelines for the treatment of multidrug-resistant Gram-negative bacterial infections 3GCephR-E=third-generation cephalosporin-resistant Enterobacterales. AmpC-E=β-lactamase producing Enterobacterales. CRAB=carbapenem-resistant Acinetobacter baumannii. CRE=carbapenem-resistant Enterobacterales. DTR-P aeruginosa=difficult-to-treat resistant-Pseudomonas aeruginosa. ESBL-E=extended-spectrum β-lactamase-producing Enterobacterales. ESCMID=European Society for Clinical Microbiology and Infectious Diseases. IDSA=Infectious Diseases Society of America. MBL=metallo-β-lactamase. UTI=urinary tract infection.
January 17, 2025 at 2:21 PM
gpollara.bsky.social
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)

N=54

All-cause 7-day and 30-day case-fatality rates = 11% & 24% respectively

@bsacandjac.bsky.social #IDSky #ClinMicro #AMR
Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)
AbstractObjectives. To assess the clinical features, antibiotic therapy and outcomes of carbapenemase-producing Enterobacterales bloodstream infection (CPE
academic.oup.com
April 14, 2025 at 9:54 PM
richard-goodman.bsky.social
As my first post on bsky post, I thought I'd share a recent paper of ours published in
@naturecomms.bsky.social
.

Here we use various techniques to determine the molecular mechanisms for an observed rise in chloramphenicol susceptibility at the same time as an increase in ESBL resistance.
Molecular mechanisms of re-emerging chloramphenicol susceptibility in extended-spectrum beta-lactamase-producing Enterobacterales - Nature Communications
In this work, authors probe the molecular mechanism of re-emerging CHL susceptibility in Malawian Enterobacterales isolates, where they identify a stable truncation of resistance genes by insertion se...
www.nature.com
December 6, 2024 at 2:55 PM